Retina World Congress is a non-profit organization dedicated to educating retina specialists on advances in the field. RWC’s main initiative is its biennial meeting, where it brings together retina societies from around the world to support global scientific and clinical exchange on advances in retina health.
The i.Profilerplus is the 4-in-1 compact system with ocular wavefront aberrometer, autorefractometer, ATLAS corneal topographer and keratometer. The fully automated measurement procedure, with easy-to-use touch screen control, enables all measurements of both eyes in approximately 60 seconds. The eye’s refractive power distribution is analysed and represented across the entire pupil aperture.
Nathan Radcliffe, MD, discusses surgical considerations for patients in whom selective laser trabeculoplasty has failed with Iqbal Ike K. Ahmed, MD, FRCSC; Arsham Sheybani, MD; and I. Paul Singh, MD. Dr. Radcliffe shares a case in which he combined implantation of the CyPass Micro-Stent (Alcon) with cataract extraction for a patient with mild open-angle glaucoma whose IOP was 19 mm Hg on three topical drops.
Свой профессиональный праздник «Международный день офтальмологии» врачи офтальмологи начали отмечать с 2004 года. Датой проведения «Международного дня офтальмологии» стало 8-е августа - день рождения знаменитого российского офтальмолога Святослава Федорова. Идея проведения «Международного дня офтальмологии» принадлежит президенту Медицинской Палаты Санкт-Петербурга Тамазу Мчедлидзе. Он обратился к офтальмологам России и зарубежных стран с предложением ежегодно проводить 8 августа бесплатные консультации и, по возможности, офтальмологические операции. "Наша общая цель - не только увековечить память Святослава Николаевича, но и продолжить благородное дело, которому он посвятил свою жизнь", - сказал он в своем обращении. Инициатива проведения «Международного дня офтальмологии» нашла поддержку не только в России, но и в США, Греции, Венгрии, Италии, Венесуэле, Чехии и других странах.
OCT Angiography – Technology Matching Pathology
OCTA, B, C – When do you (really) need OCTA?
Roberto Gallego-Pinazo, Consultant Ophthalmologist, Oftalvist, Spain
How to interpret OCTA – Practical tips for clinical use
Richard Gale, Consultant Ophthalmologist, York Teaching Hospitals NHS Foundation Trust, UK
OCTA in DME – What is the potential?
Ian Pearce, Consultant Ophthalmologist, Royal Liverpool University Hospital, UK
OCTA – Role in diagnosis and management of neovascular AMD
Konstantinos Balaskas, Consultant Ophthalmologist, Moorfields Eye Hospital, UK
The event will take place on the evening of Saturday 22nd September 2018, from 6:00 pm to 8:00 pm at the beautifully located Hilton Vienna Danube Waterfront. The hotel can be reached via free bus transfer, by subway station "Stadion" or on foot. Please find detailed information within the flyer.
VANCOUVER, British Columbia — Data for two new biosimilars for ranibizumab and bevacizumab, currently available in India, show the treatments are safe and effective for a variety of retinal diseases, according to a speaker here.
“Our data confirms that both these biosimilars are effective and safe. These could become the new safe, low-cost therapies for retinal diseases in the future,” Alay S. Banker, MD, said at the American Society of Retina Specialists annual meeting.
The prospective, consecutive case series included 22,276 eyes that received Razumab (Intas Pharmaceutical), a biosimilar to ranibizumab (Lucentis, Genentech), and 2,237 eyes that received Zybev (Cadila Healthcare), a biosimilar to bevacizumab (Avastin, Genentech). Patients in the study were treated for a variety of retinal vascular diseases, including choroidal neovascularization secondary to age-related macular degeneration, retinal vein occlusion and diabetic macular edema.
At 3-month follow-up, the mean logMAR vision of 0.72 at baseline for patients in the Razumab group experienced a statistically significant improvement to 0.54 (P < .05). The baseline central macular thickness of 406.15 µm improved to 314.1 µm, Banker said.
Patients in the Zybev group experienced a statistically significant improvement in logMAR vision of 0.68 at baseline to 0.56 at 3 months (P < .05), Banker said.
Eleven eyes in the Razumab group and four eyes in the Zybev group experienced intraocular inflammation, but no serious ocular or systemic adverse events were reported. – by Robert Linnehan
The discoverer of exfoliation was John Lindberg of Helsinki, Finland. He conducted his research as a young ophthalmology resident with the aim of elucidating 2 types of age-related degenerations of the iris and presenting it as an academic thesis. To this end, he had to construct a slit lamp, because they were not commercially available. During this investigation, he paid attention to greyish flakes and fringes on the anterior lens capsule and the pupillary border, which had not been previously described. His material consisted of 202 patients. The findings were recorded by time-consuming skillful drawings. His conclusions that the condition was age-related and often linked to chronic glaucoma and cataract are still valid today. The work was accepted as an academic thesis at the University of Helsinki in 1917.
Purpose: The aim of this study was to evaluate visual, refractive and patient satisfaction outcomes following implantation of a trifocal diffractive intraocular lens (IOL).
Patients and methods: This prospective, consecutive study included patients undergoing lens phacoemulsification of cataract and implantation of a trifocal diffractive IOL (AT LISA tri 839MP). Visual outcomes, including near, intermediate and distance visual acuity (VA), refractive error, contrast sensitivity, defocus curve and patient satisfaction were assessed preoperatively and postoperatively.
Results: Thirty IOLs were implanted in 26 patients. Distance VA improved significantly from 0.70±0.45 to 0.08±0.11 logMAR (p<0.0001) 1 week postoperatively, and to 0.07±0.13 logMAR (p<0.0001) at 1 month and 0.05±0.10 logMAR (p<0.0001) at 3 months. Uncorrected near and intermediate VA, as well as corrected near, intermediate and distance VA, were stable and maintained during the follow-up period. Preoperative anterior chamber depth demonstrated an association with effective adjustment of postoperative spherical equivalent using a regression formula (p=0.007). No significant differences were observed for VA at defocus curves of 0 to -3 D. Contrast sensitivity at each spatial frequency improved significantly at 1 week, 1 month and 3 months under photopic and photopic with glare conditions. Under mesopic and mesopic with glare conditions, significant differences were observed postoperatively at low and medium spatial frequencies. Patients reported a high level of satisfaction and an absence of glare or halo 3 months postoperatively.
Conclusion: In this study, the trifocal diffractive IOL provided excellent visual performance at all distances and improved contrast sensitivity under different conditions, resulting in high levels of patient satisfaction and spectacle independence in Chinese patients.
The long term challenges faced by people with glaucoma are numerous and important. With such a diagnosis, you have to balance many life demands, of which eye treatments are essential but by no means alone. After all, you are not living to treat glaucoma: you are living a full life into which the treatment of your condition is an intrusion
Heidelberg, Germany – Heidelberg Engineering GmbH announced today changes to the leadership team responsible to consistently deliver the company’s brand promise of excellence and innovation, supported by knowledge and confidence
his prospective, noncomparative, multicenter study was designed to evaluate the safety and efficacy of an ab interno gelatin stent (Xen Gel Stent, Allergan). Sixty-five patients aged 45 years or older with refractory open-angle glaucoma (OAG) and a history of failed filtering or cilioablative surgery and/or uncontrolled IOP (≥ 20 and ≤ 35 mm Hg) on maximum tolerated medical therapy were enrolled. The study protocol required a conjunctival peritomy to allow direct sponge application of 0.2 mg/mL mitomycin C (MMC) to the scleral bed for 2 minutes. The gelatin stent was then implanted in the sub-Tenon space in an ab interno fashion via a clear corneal incision under gonioscopic guidance, after which the conjunctiva was closed
Abstract: The rebound tonometer has a unique mechanism for measuring intraocular pressure (IOP) and has become popular worldwide due to its ease of use. The most notable advantages are the lack of an air-puff and need for topical anesthesia, ease of operation and transport, and the ability to use it with children. Four rebound tonometers (Icare® TA01i, Icare PRO, Icare HOME, and Icare ic100) are currently available for clinical examination. It is important to understand the characteristics of each tonometer and select the most appropriate one because the IOP values and the purpose of measurement are different. In this review, with the goal of improving the understanding of a range of tonometers, the issues with each device are discussed.
Purpose: Rho-associated protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM). The preclinical characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clinical development, is presented herein.
The WGA aspires in becoming the most important source of education for ophthalmologists and other healthcare providers related to glaucoma. In becoming a knowledge platform, the association offers access to the Educational Portal that includes recorded sessions from past WGC’s.
Ocular Therapeutix has resubmitted a new drug application to the FDA for its ocular pain treatment Dextenza, the company announced in a press release.
Dextenza (dexamethasone insert 0.4 mg) is a corticosteroid intracanalicular insert placed through the punctum to deliver dexamethasone for up to 30 days.
A number of international studies evaluating the sensitivity of SPECTRALIS® MultiColor confocal scanning laser ophthalmoscopy versus color fundus photography were presented at the Association for Vision and Research in Ophthalmology (ARVO) 2018 conference in Honolulu, Hawaii. The studies presented at ARVO reported better sensitivity and visualization of a number of pathologies using the SPECTRALIS MultiColor Module in comparison to color fundus photography.
In the figure below Amit Meshi, UCSD, San Diego, California, USA, et al. compared retinal pathology visualization and detection between the three technologies: SPECTRALIS MultiColor Module (image B), Optos P200 (image C) and Topcon TRC-50DX (image A). The authors concluded that whilst overall detection rate of retinal pathology was similar across all three devices, a larger area of macular involvement and significantly better epiretinal membrane (ERM) visualization was noted in the SPECTRALIS.
Dry eye symptoms are experienced by many patients, especially with aging. Unfortunately, millions of patients with ocular surface disease are underdiagnosed in the United States. Being able to detect and treat dry eye disease in its early stages is becoming increasingly important. This CME activity will discuss the etiology, pathophysiology, and new methods of diagnosis and treatment for ocular surface disorders, as well as discuss clinical cases.
Abstract: Retinitis pigmentosa (RP) is a group of heterogeneous inherited retinal degenerative disorders characterized by progressive rod and cone dysfunction and ensuing photoreceptor loss. Many patients suffer from legal blindness by their 40s or 50s. Artificial vision is considered once patients have lost all vision to the point of bare light perception or no light perception. The Argus II retinal prosthesis system is one such artificial vision device approved for patients with RP. This review focuses on the factors important for patient selection. Careful pre-operative screening, counseling, and management of patient expectations are critical for the successful implantation and visual rehabilitation of patients with the Argus II device.
Сайт основан 20 декабря 2000 года
Авторские права на дизайн и всю информацию веб-сайта www.eyenews.ru (www.glaucomanews.ru www.corneanews.ru, www.cataractanews.ruwww.retinanews.ru www.айньюс.рф www.hrtclubrussia.ru), а также на подбор и расположение материалов принадлежат учредителю и редакции вышеуказаных порталов. Использование материалов сайтов разрешено только с письменного разрешения учредителя и редакции вышеуказанных сайтов. Воспроизведение фотографий, статей и новостей, абстрактов и прочего контента любым способом без письменного разрешения запрещено и влечет ответственность, предусмотренную законодательством о защите авторских прав. Запрещается автоматизированное извлечение информации сайта любыми сервисами без официального разрешения учредителя либо редакции сайтов. При цитировании материалов ссылка наwww.eyenews.ru и другие вышеуказанные сайты обязательна.